secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avidity Biosciences, Inc. (—)
CIK:        0001599901
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001599901-24-000071
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avidity Q1 cash $915.9M, Phase 3 HARBOR trial on track, positive long-term DM1 data
--------------------------------------------------------------------------------

- Cash position $915.9M at Q1 end after $400M private placement; funding into late 2026.
- Phase 3 HARBOR trial for del-desiran in DM1 to initiate Q2 2024; FDA Breakthrough Therapy designation.
- Long-term MARINA-OLE data showed reversal of DM1 progression on vHOT, muscle strength, daily activities.
- R&D expenses $66.8M (up 40% YoY); collaboration revenue $3.5M (up 59% YoY).
- Upcoming: FSHD FORTITUDE preliminary data Q2 2024, DMD EXPLORE44 5 mg/kg data 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599901/000159990124000071/0001599901-24-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599901/000159990124000071/rna-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001599901-24-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer